Beta Drugs Ltd.
BETA · ISIN: INE351Y01019
Beta Drugs Ltd. is a small cap company in the Pharmaceuticals & Biotechnology sector, listed on the NSE under ISIN INE351Y01019.
Price and day-range figures above come from the latest NSE/BSE close, not a delayed quote. Where shown, RSI (14-day), SMA50/SMA200, and ADX measure momentum and trend from real daily closing prices - an RSI above 70 or below 30 typically signals overbought or oversold conditions, and a price above its SMA200 is a common long-term uptrend marker. ADTV (20-day average daily traded value) reflects real liquidity, not a projection. Fundamentals, when available, come from the company's own filed financials rather than a third-party estimate.
CHART
Beta Drugs Ltd. - growth of ₹100
Growth of ₹100 invested on 2025-11-28, not raw price - the standard way to compare performance regardless of price level. Daily resolution for the last 90 days, weekly up to 2 years, monthly beyond that.
1M
-9.9%
3M
-17.12%
6M
+39.06%
1Y
-
3Y CAGR
-
5Y CAGR
-
Earnings (TTM)
LEARN: Revenue and PAT · EPS · P/E
CHART
Beta Drugs Ltd. - revenue & profit (TTM)
Trailing-twelve-month figures by reported quarter, in ₹ Cr. Latest quarter: 2026-09-30.
Technicals
As of 2026-10-29.
Shareholding Pattern
CHART
Shareholding by category
As of 2026-09-30.
Corporate Actions
No corporate actions on record for this stock.
Recent Deals
No recent block/bulk/short-sell deals on record for this stock.
Frequently asked questions
What is Beta Drugs Ltd.'s latest financial performance?
Beta Drugs Ltd.'s trailing-twelve-month (TTM) revenue as of 2026-09-30 is ₹444 Cr, with a TTM profit after tax of ₹53 Cr and an EBITDA margin of 18.62%. TTM figures sum the most recent four reported quarters rather than a single quarter, which smooths out seasonal swings in a business's revenue and profit. EPS (earnings per share) over this TTM window is ₹48.7.
What is Beta Drugs Ltd.'s quality score?
Beta Drugs Ltd. has a Punji quality score of 66.7 out of 100 as of 2026-09-30. This composite score is computed from the company's reported fundamentals (profitability, balance-sheet strength, and consistency of earnings, among other factors) and is designed to be comparable across companies in different sectors. A higher score indicates a fundamentally stronger business by these measures, though it isn't a price target or a buy/sell signal - a high-quality company can still be expensively priced, and a lower-scoring one can still be a reasonable investment at the right valuation.
What do Beta Drugs Ltd.'s technical indicators show?
As of 2026-10-29, Beta Drugs Ltd.'s RSI (14-day) is 45.34 - readings above 70 typically signal an overbought stock, below 30 an oversold one, so this reading sits in neutral territory. Its 50-day moving average is currently above its 200-day moving average, a "golden cross" setup when the shorter average is above (often read as a bullish medium-term signal) or a "death cross" when below (often read as bearish). These are backward-looking statistical measures, not predictions of future price movement.
Who are the major shareholders of Beta Drugs Ltd.?
As of 2026-09-30, Beta Drugs Ltd.'s shareholding is split across Promoter (58.91%), Public (41.09%), NonPromoterNonPublic (null%). Promoter holding of 58.91% indicates the founders/controlling group's own stake in the company - a higher promoter holding is often read as a sign of management's confidence in the business, though it should be considered alongside pledge status and recent buying/selling activity, which this figure alone doesn't capture.
Stock data · Not financial advice · Past performance does not indicate future returns